Please assess the completion status of the following clinical trial:

Trial Title: Efficacy of Gaviscon-Advance® in Suppressing Post-supper Acid-pocket and Night-time Acid-reflux in Obese Participants

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Aged greater than or equal to 18 years and less than or equal to 70 years.~2. BMI \>27.5 (based on kg/m2)~4. Not taking acid suppressant PPI and H2 receptor blockers 5. Not taking antacids or alginate preparations, except those administered as part of study procedure.~Exclusion Criteria:~1. Those with gastrointestinal symptoms indicative of GERD, gastric carcinoma, previous or current peptic ulcer disease.~2. Those with a history of upper GI surgery prior to this.~3. Those with haematological disorders, bleeding tendency, recurrent nose bleeds or treatment with anti-coagulants).~4. Those who had any previous history of allergy or known intolerance to any of the study drugs or the following formulation constituents: Gaviscon® liquid: sodium alginate, sodium bicarbonate and calcium carbonate~5. Those with physical, neurological or psychiatric conditions preventing repeated visits to hospital or compliance with study procedures.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: t

Study Arms:
- Alginate-antacid group (Type: EXPERIMENTAL): Participants will take normal meals with late night supper (i.e.two chicken burgers and one cup or 250 ml of teh-tarik) plus alginate-antacid.
- Non antacid alginate group (Type: EXPERIMENTAL): Participants will take normal meals with late night supper (i.e.two chicken burgers and one cup or 250 ml of teh-tarik) plus antacid alone.

Based on this trial design, predict the completion outcome and termination type (if applicable).